TYNDALL CAPITAL PARTNERS L P
CIK 1219314 · View on SEC EDGAR ↗
- Portfolio value
- $452K
- Positions
- 1
- As of
- June 30, 2025 Data as of Q2 2025
#9,241 of 9,443 by 13F value · top 97.9%
Portfolio value QoQ: +9.6% 13F does not disclose cash
- Top 10 holdings weight
- 100.00%
- Top 25 holdings weight
- 100.00%
- Positions above 1%
- 1
- Effective number of positions
- 1.0
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2025: 0.0% Est. buys $0 · sells $27,907
- New positions
- 0
- Increased
- 0
- Decreased
- 1
- Closed
- 0
On this page
- Performance vs S&P How this manager's 13F portfolio performed against the S&P 500.
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- Top moves The biggest position increases and decreases this quarter.
- Related The person behind this filer, where we can match one.
Performance vs S&P 500
Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.
Priceable coverage: 100.0% · Options excluded: 0.0%
Sector breakdown
Healthcare
100.0%
Full portfolio 1 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| CYCN Cyclerion Therapeutics, Inc. - Common Stock | $451,594 | 100.00% | 155,187 | $39,651 | Down ×1 | ||
| No matches | |||||||
Top movers (QoQ)
| Security | Action | Shares Δ | Value Δ |
|---|---|---|---|
| CYCN | Trimmed | -10K | +$40K |